ID   KATO III
AC   CVCL_0371
SY   Kato III; Kato-III; KATO-III; KATOIII; KatoIII; KATO 3; JTC-28; Japanese Tissue Culture-28
DR   BTO; BTO:0001092
DR   CLO; CLO_0007073
DR   CLO; CLO_0050790
DR   EFO; EFO_0002217
DR   MCCL; MCC:0000266
DR   CLDB; cl5214
DR   CLDB; cl3000
DR   AddexBio; C0023001/53
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-103
DR   BCRC; 60200
DR   BCRJ; 0318
DR   BioGRID_ORCS_Cell_line; 909
DR   BioSample; SAMN01821574
DR   BioSample; SAMN01821690
DR   BioSample; SAMN03471089
DR   BioSample; SAMN03473264
DR   BioSample; SAMN10988331
DR   cancercelllines; CVCL_0371
DR   CCRID; 3101HUMSCSP573
DR   CCRID; 3101HUMTCHu229
DR   CCTCC; GDC0253
DR   Cell_Model_Passport; SIDM00687
DR   CGH-DB; 122-1
DR   CGH-DB; 9024-4
DR   ChEMBL-Cells; CHEMBL3308432
DR   ChEMBL-Targets; CHEMBL612700
DR   CLS; 300381
DR   Cosmic; 685595
DR   Cosmic; 687555
DR   Cosmic; 755614
DR   Cosmic; 801336
DR   Cosmic; 848150
DR   Cosmic; 848375
DR   Cosmic; 877044
DR   Cosmic; 887248
DR   Cosmic; 888823
DR   Cosmic; 889107
DR   Cosmic; 907276
DR   Cosmic; 922690
DR   Cosmic; 926118
DR   Cosmic; 968350
DR   Cosmic; 1001657
DR   Cosmic; 1067210
DR   Cosmic; 1090464
DR   Cosmic; 1093302
DR   Cosmic; 1187279
DR   Cosmic; 1223583
DR   Cosmic; 1518254
DR   Cosmic; 1571766
DR   Cosmic; 1627262
DR   Cosmic; 1890472
DR   Cosmic; 2009529
DR   Cosmic; 2036664
DR   Cosmic; 2069771
DR   Cosmic; 2484964
DR   Cosmic; 2807629
DR   Cosmic; 2823224
DR   Cosmic-CLP; 907276
DR   DepMap; ACH-000793
DR   ECACC; 86093004
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 907276
DR   GEO; GSM267419
DR   GEO; GSM267426
DR   GEO; GSM267433
DR   GEO; GSM267440
DR   GEO; GSM552362
DR   GEO; GSM562404
DR   GEO; GSM827547
DR   GEO; GSM828835
DR   GEO; GSM844573
DR   GEO; GSM887200
DR   GEO; GSM888273
DR   GEO; GSM1237676
DR   GEO; GSM1237701
DR   GEO; GSM1250898
DR   GEO; GSM1250899
DR   GEO; GSM1250900
DR   GEO; GSM1250901
DR   GEO; GSM1374593
DR   GEO; GSM1374594
DR   GEO; GSM1669980
DR   IARC_TP53; 21648
DR   IGRhCellID; KATOIII
DR   IZSLER; BS TCL 151
DR   JCRB; JCRB0611
DR   JCRB; NIHS0052
DR   KCB; KCB 2014045YJ
DR   KCLB; 30103
DR   LiGeA; CCLE_710
DR   LINCS_HMS; 50022
DR   LINCS_LDP; LCL-2003
DR   NCBI_Iran; C640
DR   PharmacoDB; KATOIII_737_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0371
DR   PubChem_Cell_line; CVCL_0371
DR   RCB; RCB2088
DR   TKG; TKG 0213
DR   Wikidata; Q54899539
RX   CelloPub=CLPUB00581;
RX   CelloPub=CLPUB00584;
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   DOI=10.2198/sbk.34.289;
RX   PubMed=209229;
RX   PubMed=1370612;
RX   PubMed=1778766;
RX   PubMed=1933850;
RX   PubMed=3518877;
RX   PubMed=3962675;
RX   PubMed=6862145;
RX   PubMed=9023415;
RX   PubMed=9247707;
RX   PubMed=9290701;
RX   PubMed=11107048;
RX   PubMed=11314020;
RX   PubMed=15723654;
RX   PubMed=17505008;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=24587255;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29435981;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32028591;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 36 hours (PubMed=209229); 32-34 hours (PubMed=3962675); 36 hours (PubMed=29435981); 37-41 hours (CelloPub=CLPUB00584).
CC   HLA typing: A*02,24:02; B*15:01,46:01; C*01:02,03:03 (PubMed=9023415).
CC   HLA typing: A*02:07,02:07; B*15:01,46:01; C*01:02,01:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*08:03,15:01 (PubMed=25960936).
CC   HLA typing: A*02:07,02:07; B*15:01,46:01; C*01:02,03:03; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*08:03,15:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=1370612; PubMed=1933850; PubMed=11107048).
CC   Omics: ChIP-seq GATA4 analysis.
CC   Omics: ChIP-seq GATA6 analysis.
CC   Omics: ChIP-seq KLF5 analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.78%; Native American=0%; East Asian, North=78.55%; East Asian, South=19.58%; South Asian=1.02%; European, North=0.06%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0052; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; ECACC; JCRB; KCLB; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 7,11
ST   D13S317: 8,12
ST   D16S539: 10,12
ST   D18S51: 12
ST   D21S11: 30,31
ST   D3S1358: 15,16
ST   D5S818: 10,11
ST   D7S820: 8,12 (AddexBio; ATCC; CLS; Cosmic-CLP; ECACC; JCRB; KCLB; RCB; TKG)
ST   D7S820: 12 (PubMed=25877200)
ST   D8S1179: 13,14
ST   FGA: 23,24 (CLS; KCLB)
ST   FGA: 23,25 (PubMed=25877200)
ST   Penta D: 13,14
ST   Penta E: 13,18,19
ST   TH01: 7,9
ST   TPOX: 11
ST   vWA: 14,16
DI   NCIt; C2993; Down syndrome
DI   NCIt; C5250; Gastric signet ring cell adenocarcinoma
DI   ORDO; Orphanet_870; Down syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M882 ! KATO II
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
//
RX   CelloPub=CLPUB00581;
RA   Hojo H.;
RT   "Establishment of cultured cell lines of human stomach cancer origin
RT   and their morphological characteristics.";
RL   Niigata Igakkai Zasshi 91:737-763(1977).
//
RX   CelloPub=CLPUB00584;
RA   Motoyama T., Hojo H., Suzuki T., Oboshi S.;
RT   "Evaluation of the regrowth assay method as an in vitro drug sensitivity
RT   test and its application to cultured human gastric cancer cell lines.";
RL   Acta Med. Biol. 27:49-63(1979).
//
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994).
//
RX   DOI=10.2198/sbk.34.289;
RA   Mizusawa H.;
RT   "Operation of the JCRB cell bank and isoenzyme.";
RL   Seibutsu Butsuri Kagaku 34:289-292(1990).
//
RX   PubMed=209229;
RA   Sekiguchi M., Sakakibara K., Fujii G.;
RT   "Establishment of cultured cell lines derived from a human gastric
RT   carcinoma.";
RL   Jpn. J. Exp. Med. 48:61-68(1978).
//
RX   PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0;
RA   Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O.,
RA   Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.;
RT   "Missense mutations and a deletion of the p53 gene in human gastric
RT   cancer.";
RL   Biochem. Biophys. Res. Commun. 182:215-223(1992).
//
RX   PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x;
RA   Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M.,
RA   Ohnishi Y., Xiao H.-Y., Nagai Y., Takagi H.;
RT   "Aberrant elevation of tyrosine-specific phosphorylation in human
RT   gastric cancer cells.";
RL   Jpn. J. Cancer Res. 82:1428-1435(1991).
//
RX   PubMed=1933850;
RA   Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S.,
RA   Nakatani K., Nakano H., Sugimura T., Terada M.;
RT   "p53 gene mutations in gastric cancer metastases and in gastric cancer
RT   cell lines derived from metastases.";
RL   Cancer Res. 51:5800-5805(1991).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3962675; DOI=10.1111/j.1440-1827.1986.tb01461.x;
RA   Motoyama T., Hojo H., Watanabe H.;
RT   "Comparison of seven cell lines derived from human gastric
RT   carcinomas.";
RL   Acta Pathol. Jpn. 36:65-83(1986).
//
RX   PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240;
RA   Naito S., Inoue S., Kinjo M., Tanaka K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human gastric
RT   cancer cell lines.";
RL   Gann 74:240-247(1983).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9247707; DOI=10.1080/15216549700202901;
RA   Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.;
RT   "Expression of bone morphogenetic proteins of human neoplastic
RT   epithelial cells.";
RL   Biochem. Mol. Biol. Int. 42:497-505(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x;
RA   Yokozaki H.;
RT   "Molecular characteristics of eight gastric cancer cell lines
RT   established in Japan.";
RL   Pathol. Int. 50:767-777(2000).
//
RX   PubMed=11314020; DOI=10.1038/sj.onc.1204160;
RA   Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T.,
RA   Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.;
RT   "Alpha-fetoprotein producing gastric cancer lacks transcription factor
RT   ATBF1.";
RL   Oncogene 20:869-873(2001).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=17505008; DOI=10.1158/1078-0432.CCR-06-2743;
RA   Takeda M., Arao T., Yokote H., Komatsu T., Yanagihara K., Sasaki H.,
RA   Yamada Y., Tamura T., Fukuoka K., Kimura H., Saijo N., Nishio K.;
RT   "AZD2171 shows potent antitumor activity against gastric cancer
RT   over-expressing fibroblast growth factor receptor 2/keratinocyte
RT   growth factor receptor.";
RL   Clin. Cancer Res. 13:3051-3057(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24587255; DOI=10.1371/journal.pone.0090155;
RA   Endo F., Nishizuka S.S., Kume K., Ishida K., Katagiri H., Ishida K.,
RA   Sato K., Iwaya T., Koeda K., Wakabayashi G.;
RT   "A compensatory role of NF-kappaB to p53 in response to 5-FU-based
RT   chemotherapy for gastric cancer cell lines.";
RL   PLoS ONE 9:E90155-E90155(2014).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32028591; DOI=10.3390/cancers12020334;
RA   Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H.,
RA   Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.;
RT   "TDP1 and TOP1 modulation in olaparib-resistant cancer determines the
RT   efficacy of subsequent chemotherapy.";
RL   Cancers (Basel) 12:334.1-334.17(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//